Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease

被引:50
作者
Ecder, T
Edelstein, CL
Chapman, AB
Johnson, AM
Tison, L
Gill, EA
Brosnahan, GM
Schrier, RW
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Med, Sch Med,Div Renal Dis & Hypertens, Denver, CO 80262 USA
[2] Univ Colorado, Sch Med, Div Cardiol, Dept Med, Denver, CO 80262 USA
[3] Emory Univ, Sch Med, Div Renal, Atlanta, GA 30322 USA
关键词
ACE inhibitors; left ventricular hypertrophy; polycystic kidney disease;
D O I
10.1093/ndt/14.5.1113
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Hypertension occurs commonly and early in the natural history of autosomal dominant polycystic kidney disease (ADPKD), affecting both renal and patient outcome. Activation of the renin-angiotensin-aldosterone system due to cyst expansion and local renal ischaemia plays an important role in the development of ADPKD related hypertension and left ventricular hypertrophy (LVH), a known important risk factor for cardiovascular morbidity and mortality. The aim of this study was to investigate the effects of an angiotensin converting enzyme (ACE) inhibitor, enalapril, on renal function, blood pressure and LVH in hypertensive ADPKD patients. Methods. Fourteen hypertensive ADPKD patients (II men, 3 women; mean age: 40 years) were included in the study. All patients had LVH and creatinine clearance (Cer) greater than 50ml/min/1.73m(2). The patients were followed for 7 years on enalapril therapy. The effects of enalapril on renal function, blood pressure and LVH were investigated. Results. Baseline measurements of mean arterial pressure (MAP), Ccr and left ventricular mass index (LVMI) were 110+/-2mmHg, 84+/-6ml/min/1.73m(2) and 146 +/- 4 g/m(2), respectively. After one year of enalapril therapy there was a significant decrease in MAP (94 +/- 3 mmHg, P< 0.005) which remained stable until the end of the study at 7 years (94 +/- 1 mmHg, P < 0.005 vs baseline). There was also a significant decrease in LVMI (131+/-6 g/m(2), P< 0.05) after year I which continued to decrease until the end of the study reaching 98 +/- 6 g/m(2) (P < 0.01 vs year 1 and baseline). Although Ccr remained stable after year I, a significant decrease was observed after 7 years of follow-up (59 +/- 6 ml/min, P<0.001 vs year 1 and baseline). Conclusions. ACE inhibition in hypertensive ADPKD patients provided long-term reversal of LVH in association with a mean 3.6 ml/min/year decline of Ccr. These preliminary results have potential important implications for cardiovascular and renal protection in ADPKD.
引用
收藏
页码:1113 / 1116
页数:4
相关论文
共 23 条
[1]  
Chapman AB, 1997, J AM SOC NEPHROL, V8, P1292
[2]   THE RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM AND AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
CHAPMAN, AB ;
JOHNSON, A ;
GABOW, PA ;
SCHRIER, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (16) :1091-1096
[3]   REVERSIBLE RENAL-FAILURE ASSOCIATED WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS IN POLYCYSTIC KIDNEY-DISEASE [J].
CHAPMAN, AB ;
GABOW, PA ;
SCHRIER, RW .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (10) :769-773
[4]   REVERSAL OF LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS - A METAANALYSIS OF 109 TREATMENT STUDIES [J].
DAHLOF, B ;
PENNERT, K ;
HANSSON, L .
AMERICAN JOURNAL OF HYPERTENSION, 1992, 5 (02) :95-110
[5]   LEFT-VENTRICULAR MASS IN CHILDREN AND ADOLESCENTS [J].
DEVEREUX, RB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 12 (03) :709-711
[6]   ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure [J].
Dyadyk, AI ;
Bagriy, AE ;
Lebed, IA ;
Yarovaya, NF ;
Schukina, EV ;
Taradin, GG .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (05) :945-951
[7]  
Dzau V J, 1988, Am J Med, V84, P22, DOI 10.1016/0002-9343(88)90201-X
[8]   Vasoactive hormones and renal sclerosis - Discussion [J].
Egido, J .
KIDNEY INTERNATIONAL, 1996, 49 (02) :578-597
[9]  
FICK GM, 1995, J AM SOC NEPHROL, V5, P2048
[10]   Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
KIDNEY INTERNATIONAL, 1996, 49 (05) :1379-1385